Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial

Clinical trial NCT07165769 · RECRUITING

Trial details

NCT number: NCT07165769
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Splenic B-cell Lymphoma/Leukaemia With Prominent Nucleoli，SBLPN

Start date: 2025-09-04
Primary completion: 2028-12-31
Enrollment: 47

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.